丙型肝炎病毒感染人体模型中的免疫监测。
Immunological Monitoring in Hepatitis C Virus Controlled Human Infection Model.
机构信息
Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada.
Département de Médecine, Université de Montréal, Montréal, Québec, Canada.
出版信息
Clin Infect Dis. 2023 Aug 14;77(Suppl 3):S270-S275. doi: 10.1093/cid/ciad359.
Abstract
Controlled human infection model trials for hepatitis C virus represent an important opportunity to identify correlates of protective immunity against a well-characterized inoculum of hepatitis C virus and how such responses are modified by vaccination. In this article, we discuss the approach to immunological monitoring during such trials, including a set of recommendations for optimal sampling schedule and preferred immunological assays to examine the different arms of the immune response. We recommend that this approach be adapted to different trial designs. Finally, we discuss how these studies can provide surrogate predictors of the success of candidate vaccines.
摘要
用于丙型肝炎病毒的人体感染控制模型试验代表了一个重要的机会，可以确定针对丙型肝炎病毒的特征性接种物的保护性免疫相关因素，以及这种反应如何通过疫苗接种来改变。在本文中，我们讨论了在这种试验中进行免疫监测的方法，包括一套最佳采样计划和首选免疫测定的建议，以检查免疫反应的不同方面。我们建议根据不同的试验设计来调整这种方法。最后，我们讨论了这些研究如何为候选疫苗的成功提供替代预测指标。
相似文献
1
Immunological Monitoring in Hepatitis C Virus Controlled Human Infection Model.丙型肝炎病毒感染人体模型中的免疫监测。
Clin Infect Dis. 2023 Aug 14;77(Suppl 3):S270-S275. doi: 10.1093/cid/ciad359.
2
Modified E2 Glycoprotein of Hepatitis C Virus Enhances Proinflammatory Cytokines and Protective Immune Response.丙型肝炎病毒 E2 糖蛋白修饰增强前炎症细胞因子和保护性免疫应答。
J Virol. 2022 Jun 22;96(12):e0052322. doi: 10.1128/jvi.00523-22. Epub 2022 May 25.
3
Hepatitis C Virus Vaccine Research: Time to Put Up or Shut Up.丙型肝炎病毒疫苗研究：是时候拿出成果或闭嘴了。
Viruses. 2021 Aug 12;13(8):1596. doi: 10.3390/v13081596.
4
Protective immunity against hepatitis C virus infection.针对丙型肝炎病毒感染的保护性免疫。
Immunol Cell Biol. 2006 Jun;84(3):239-49. doi: 10.1111/j.1440-1711.2006.01427.x.
5
Priming of Antiviral CD8 T Cells without Effector Function by a Persistently Replicating Hepatitis C-Like Virus.持续复制的丙型肝炎样病毒对抗病毒 CD8 T 细胞的启动而无效应功能。
J Virol. 2020 May 4;94(10). doi: 10.1128/JVI.00035-20.
6
Complete definition of immunological correlates of protection and clearance of hepatitis C virus infection: a relevant pending task for vaccine development.全面定义丙型肝炎病毒感染的免疫保护和清除相关性：疫苗开发的一个相关待解决任务。
Int Rev Immunol. 2012 Jun;31(3):223-42. doi: 10.3109/08830185.2012.680552.
7
Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.DNA 启动的 RNA 复制子和改良安卡拉痘苗病毒 HCV 疫苗接种诱导小鼠产生强效抗丙型肝炎病毒 (HCV) T 细胞免疫应答。
J Virol. 2019 Mar 21;93(7). doi: 10.1128/JVI.00055-19. Print 2019 Apr 1.
8
Molecular Determinants of Mouse Adaptation of Rat Hepacivirus.鼠适应大鼠肝炎病毒的分子决定因素。
J Virol. 2023 Apr 27;97(4):e0181222. doi: 10.1128/jvi.01812-22. Epub 2023 Mar 27.
9
A Multiantigenic DNA Vaccine That Induces Broad Hepatitis C Virus-Specific T-Cell Responses in Mice.一种在小鼠中诱导广泛丙型肝炎病毒特异性T细胞应答的多抗原DNA疫苗。
J Virol. 2015 Aug;89(15):7991-8002. doi: 10.1128/JVI.00803-15. Epub 2015 May 27.
10
Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations.用于丙型肝炎病毒疫苗开发的人体感染控制模型：试验设计考虑因素。
Clin Infect Dis. 2023 Aug 14;77(Suppl 3):S262-S269. doi: 10.1093/cid/ciad362.
引用本文的文献
1
Theoretical modeling of hepatitis C acute infection in liver-humanized mice support pre-clinical assessment of candidate viruses for controlled-human-infection studies.肝脏人源化小鼠丙型肝炎急性感染的理论模型支持对用于可控人类感染研究的候选病毒进行临床前评估。
Sci Rep. 2024 Dec 30;14(1):31826. doi: 10.1038/s41598-024-83104-0.
2
Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations.用于丙型肝炎病毒疫苗开发的人体感染控制模型：试验设计考虑因素。
Clin Infect Dis. 2023 Aug 14;77(Suppl 3):S262-S269. doi: 10.1093/cid/ciad362.
本文引用的文献
1
Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations.用于丙型肝炎病毒疫苗开发的人体感染控制模型：试验设计考虑因素。
Clin Infect Dis. 2023 Aug 14;77(Suppl 3):S262-S269. doi: 10.1093/cid/ciad362.
2
Volunteering for Infection: Participant Perspectives on a Hepatitis C Virus Controlled Human Infection Model.自愿感染：参与者对丙型肝炎病毒人工感染模型的看法。
Clin Infect Dis. 2023 Aug 14;77(Suppl 3):S224-S230. doi: 10.1093/cid/ciad350.
3
Single-cell RNA sequencing of liver fine-needle aspirates captures immune diversity in the blood and liver in chronic hepatitis B patients.肝细针穿刺活组织检查单细胞 RNA 测序捕获慢性乙型肝炎患者血液和肝脏中的免疫多样性。
Hepatology. 2023 Nov 1;78(5):1525-1541. doi: 10.1097/HEP.0000000000000438. Epub 2023 May 10.
4
Single-cell atlas of the liver myeloid compartment before and after cure of chronic viral hepatitis.慢性病毒性肝炎治愈前后肝脏髓系细胞图谱
J Hepatol. 2024 Feb;80(2):251-267. doi: 10.1016/j.jhep.2023.02.040. Epub 2023 Mar 25.
5
Pan-vaccine analysis reveals innate immune endotypes predictive of antibody responses to vaccination.泛疫苗分析揭示了预测疫苗接种后抗体反应的固有免疫内型。
Nat Immunol. 2022 Dec;23(12):1777-1787. doi: 10.1038/s41590-022-01329-5. Epub 2022 Oct 31.
6
Transcriptional atlas of the human immune response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses.人类对 13 种疫苗的免疫反应转录图谱揭示了一种预测疫苗诱导抗体反应的共同指标。
Nat Immunol. 2022 Dec;23(12):1788-1798. doi: 10.1038/s41590-022-01328-6. Epub 2022 Oct 31.
7
Liver-resident memory T cells: life in lockdown.肝脏驻留记忆 T 细胞： lockdown 生活。
Semin Immunopathol. 2022 Nov;44(6):813-825. doi: 10.1007/s00281-022-00932-w. Epub 2022 Apr 28.
8
An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development.用于丙型肝炎病毒疫苗开发的具有抗原多样性的代表性包膜糖蛋白面板。
Gastroenterology. 2022 Feb;162(2):562-574. doi: 10.1053/j.gastro.2021.10.005. Epub 2021 Oct 13.
9
T cell responses during HBV and HCV infections: similar but not quite the same?HBV 和 HCV 感染期间的 T 细胞反应：相似但不完全相同？
Curr Opin Virol. 2021 Dec;51:80-86. doi: 10.1016/j.coviro.2021.08.011. Epub 2021 Oct 4.
10
Towards a Systems Immunology Approach to Understanding Correlates of Protective Immunity against HCV.朝着理解 HCV 保护性免疫相关因素的系统免疫学方法发展。
Viruses. 2021 Sep 18;13(9):1871. doi: 10.3390/v13091871.
Zotero 插件